Asciminib found to be safe and effective for heavily pretreated patients with chronic myeloid leukaemia in chronic phase from first class email sign in Watch Video
Preview(s): Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Your browser does not support playing the video.Please download the video!
Description: Dr Michael Mauro speaks to ecancer in an online interview for the ASH 2021 meeting about updated safety and efficacy results from the ASCEMBL study. nnDr Mauro explains that this phase III trial used asciminib, a first-in-class STAMP inhibitor, vs bosutinib in patients with chronic myeloid leukaemia in chronic phase (CML-CP) after prior treatment with tyrosine kinase inhibitors (TKIs). nnHe reports that this update found asciminib to have a positive benefit-risk profile, supporting its use in th